行情

MNOV

MNOV

美第奇新星生物技术
NASDAQ

实时行情|Nasdaq Last Sale

7.71
+0.10
+1.31%
已收盘, 16:00 11/14 EST
开盘
7.67
昨收
7.61
最高
7.75
最低
7.61
成交量
3.75万
成交额
--
52周最高
13.37
52周最低
6.68
市值
3.38亿
市盈率(TTM)
-29.5856
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MNOV 新闻

  • Here is What Hedge Funds Think About MediciNova, Inc. (MNOV)
  • Insider Monkey.11/06 18:50
  • MNOV: Phase 3 Trial Initiated for MN-166 in ALS
  • Zacks Small Cap Research.10/31 00:00
  • MediciNova nabs new Canadian patent covering ibudilast
  • seekingalpha.10/28 15:45
  • MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
  • GlobeNewswire.10/28 11:00

更多

所属板块

生物技术和医学研究
-0.05%
制药与医学研究
-0.27%

热门股票

名称
价格
涨跌幅

MNOV 简况

Medicinova, Inc. is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin). MN-166 is an oral, anti-inflammatory and neuroprotective agent. MN-166 is in development for the treatment of several neurological diseases, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, and substance dependence and addiction. MN-001 (tipelukast) is an orally bioavailable small molecule compound, which is used for the treatment of fibrotic diseases, such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis. MN-221 treats acute exacerbations of asthma through intravenous infusion, bypassing constricted airways to deliver the drug to the lungs. MN-029 is used for the treatment of solid tumor cancers.
展开

Webull提供MediciNova, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。